Chemotherapy-induced peripheral neuropathies in hematological malignancies
- 19 October 2014
- journal article
- review article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 121 (2) , 229-237
Abstract
Recent developments in the treatment of hematological malignancies, especially with the advent of proteasome inhibitors and immunomodulatory drugs in plasma cell dyscrasias, call for an increased collaboration between hematologists and neurologists. This collaboration involves differentiating chemotherapy-induced peripheral neuropathies (CiPN) from disease-related neurologic complications, early recognition of CiPN and treatment of neuropathic pain. Multiple myeloma, Waldenstrom’s macroglobulinemia and light-chain amyloidosis frequently present with peripheral neuropathy. In addition, multiple myeloma, non-Hodgkin lymphomas and leukemia’s may mimic peripheral neuropathy by compression or invasion of the extra/intradural space. Platinum compounds, vinca alkaloids, proteasome inhibitors and immunomodulatory drugs may all cause CiPN, each with different and often specific clinical characteristics. Early recognition, by identifying the distinct clinical phenotype of CiPN, is of crucial importance to prevent irreversible neurological damage. No recommendations can be given on the use of neuroprotective strategies because of a lack of convincing clinical evidence. Finally, CiPN caused by vinca-alkaloids, proteasome inhibitors and immunomodulatory drugs is often painful and neurologists are best equipped to treat this kind of painful neuropathy.Keywords
This publication has 56 references indexed in Scilit:
- Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathyExperimental Neurology, 2012
- The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findingsAnnals of Oncology, 2012
- Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patientsHaematologica, 2011
- Cisplatin induced Mitochondrial DNA damage in dorsal root ganglion neuronsNeurobiology of Disease, 2011
- Treatment-related peripheral neuropathy in multiple myeloma: the challenge continuesThe Lancet Oncology, 2010
- Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and NeuropathyJournal of Clinical Oncology, 2009
- Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2007
- Paclitaxel- and vincristine-evoked painful peripheral neuropathies: Loss of epidermal innervation and activation of Langerhans cellsExperimental Neurology, 2006
- Thalidomide for Patients With Relapsed Multiple Myeloma After High-Dose Chemotherapy and Stem Cell Transplantation: Results of an Open-Label Multicenter Phase 2 Study of Efficacy, Toxicity, and Biological ActivityMayo Clinic Proceedings, 2004
- Neurotoxicity is not enhanced by increased dose intensities of cisplatin administrationEuropean Journal of Cancer, 1995